PAM
LXEO icon

Panagora Asset Management’s Lexeo Therapeutics LXEO Stock Holding History

Panagora Asset Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,297
Closed -$197K – 1247
2026
Q1 		$197K Hold
34,297
– – ﹤0.01% 1104
2025
Q4 		$341K Hold
34,297
– – ﹤0.01% 966
2025
Q3 		$228K Sell
34,297
-444
-1% -$2.15K ﹤0.01% 1053
2025
Q2 		$140K Hold
34,741
– – ﹤0.01% 1080
2025
Q1 		$121K Buy
+34,741
New +$154K ﹤0.01% 1071

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Panagora Asset Management's LXEO Position: Q2 2026 in Review

Panagora Asset Management sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 34,297 shares — an estimated $197K sold.

Panagora Asset Management first reported a position in LXEO in Q1 2025 and held it in 5 quarters. The position peaked at $341K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Panagora Asset Management reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Panagora Asset Management sold 34,297 Lexeo Therapeutics shares in Q2 2026, an estimated $197K.
  • Panagora Asset Management first reported a position in Lexeo Therapeutics in Q1 2025 and held it in 5 quarters.
  • Panagora Asset Management's Lexeo Therapeutics position peaked at $341K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.